CTLA4 and ovarian carcinoma: Recent immunotherapeutic approaches to kill ovarian cancer cells through CTLA-4, PD-1/PD-L1, and other immune target inhibitors such as Pembrolizumab and Nivolumab to interfere with immune modulation in ovarian cancer TME have shown initial success, and immunotherapy with VISTA and ovarian cancer is in full swing [27–29].